Int. Journal of Clinical Pharmacology and Therapeutics, Volume 52 - September (726 - 731)

Impact of comorbidities on the treatment of atopic dermatitis in clinical practice
Alexandra Werner-Busse1, Karel Kostev2, Guido Heine1, Margitta Worm1
1 Department of Dermatology, Venereology and Allergology, Charité Universitätsmedizin Berlin, Berlin, and 2 IMS Health Epidemiology and Pharmacovigilance, Frankfurt am Main, German

Add to Cart  

 

DOI 10.5414/CP202040

Abstract

Background and aim: Atopic dermatitis is often associated with atopic comorbidities such as allergic rhinitis, allergic asthma and food allergy. The aim of the present study was to analyze treatment data pertaining to atopic dermatitis patients in Germany with regard to the presence of other atopic comorbidities in the primary care and to investigate whether the presence of atopic codiagnoses has an impact on the treatment of atopic dermatitis (AD) patients. Methods: We used data from the Disease Analyzer database (IMS HEALTH, Germany) including 1,631 physicians (general practitioners, dermatologists and pediatricians) and 3.3 million patients. 39,642 (7.5%) of these patients were treated by dermatologists, 17,124 (5.2%) by pediatricians and 15,774 (0.9%) by general practitioners and had a documented diagnosis of atopic dermatitis. Results: 46.4% of AD patients treated by general practitioners, 42.5% by dermatologists and 32.0% by pediatricians were codiagnosed with one defined atopic diseases (allergic asthma, urticaria, allergic rhinitis and food allergy). In patients without AD, the proportion of atopic diseases was significantly smaller (41.4% for those treated by general practitioners, 38.4% for those treated by dermatologists, 26.4% for those treated by pediatricians). AD patients with another atopic comorbidity received topical corticosteroids (CS) (42.5%) more frequently than those without comorbidity (46.4% vs. 41.4% for patients treated by general practitioners, 42.5% vs. 38.4% for patients treated by dermatologists, 32.0% vs. 26.4% for patients treated by pediatricians). The general practitioners and pediatricians prescribed systemic corticosteroids to 13.2% and 7.8% of AD patients with additional atopic diseases, while the rate was only 5.1% and 3.0% in patients without comorbidities. Conclusion: In AD patients, the share of patients diagnosed with atopic diseases is significantly higher than in patients without AD. AD outpatients with concomitant atopic comorbidities receive topical, but also systemic corticosteroid prescriptions more frequently.

Author Details

Authors

Departments

  • 1 Department of Dermatology, Venereology and Allergology, Charité Universitätsmedizin Berlin, Berlin, and
  • 2 IMS Health Epidemiology and Pharmacovigilance, Frankfurt am Main, German

Address

Dr. Karel Kostev
IMS Health – Epidemiologie and Pharmacovigilance
Darmstädter Straße 108
60598 Frankfurt am Main, Germany
Email: [email protected]

Citation

Alexandra Werner-Busse, Karel Kostev, Guido Heine, and Margitta Worm.Impact of comorbidities on the treatment of atopic dermatitis in clinical practice. 2014; 52: 726-731. doi: 10.5414/CP202040.

###article_not_exists_msg###

Shopping Overview

Shopping Overview
Type Qtty Discount VAT Price
Your basket is empty
View Cart